The MorphoSys Share

(During the 2010 fiscal year, MorphoSys’s stock price increased by 9 %, outperforming the Tec DAX, which showed only a moderate annual growth of 4 %. The NASDAQ biotechnology index rose by 14 % in 2010.)

KEY DATA FOR THE MORPHOSYS SHARE

(as of December 31 of each year, in € million, if not stated otherwise)

in million €	2010	2009	2008	2007	2006
Total Stockholders’ Equity	185.9	173.9	162.0	145.5	100.1
Number of Shares Issued (Total)	22,890,252	22,660,557	22,478,787	22,160,259	20,145,996
Market Capitalization	424	386	421	357	365
€ Closing Price (Xetra)	18.53	17.04	18.75	16.10	18.12
Average Daily Trading Volume	1.1	1.3	1.9	2.5	1.9

The stock’s performance benefited in particular from the acquisition of Sloning, the agreement with Pfizer, and the multiple milestones that were reached in the final month of the year. Overall, the MorphoSys share price is beginning to reflect the Company’s solid progress in building one of the most extensive antibody pipelines in the industry, together with a profitable and convincing business model.

LIQUIDITY AND INDEX MEMBERSHIP

The average daily trading volume of MorphoSys’s stock was € 1.1 million per day, compared to an average trading volume of € 1.3 million per day in the previous year. MorphoSys consolidated its strong position in the TecDAX index, which includes the 30 largest technology stocks on the Frankfurt Stock Exchange. At the end of 2010, the Company was able to improve its position based on market capitalization to place 16 (year-end 2009: 17th place) and occupied 23rd position based on trading volume (year-end 2009: 19th position).

STOCKHOLDER BASE

The free float according to Deutsche Börse AG, which is generally taken into account in the weighting of MorphoSys’s stock in stock indices, was 88 % of the share capital at year-end 2010.

Please visit our website for the most recent information on investor relations.